Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms

Description

This is a prospective observational multi-center pilot study of germline testing for participants receiving care at University of California participating locations with a new or existing diagnosis of Pancreatic Neuroendocrine Neoplasms (PanNEN). This protocol is an extension of existing Genetic Testing Station efforts at University of California, San Francisco (UCSF)

Conditions

Pancreatic Neuroendocrine Neoplasm

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a prospective observational multi-center pilot study of germline testing for participants receiving care at University of California participating locations with a new or existing diagnosis of Pancreatic Neuroendocrine Neoplasms (PanNEN). This protocol is an extension of existing Genetic Testing Station efforts at University of California, San Francisco (UCSF)

Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms

Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms

Condition
Pancreatic Neuroendocrine Neoplasm
Intervention / Treatment

-

Contacts and Locations

Los Angeles

University of California, Los Angeles, Los Angeles, California, United States, 90095

San Diego

Univeristy of California, San Diego, San Diego, California, United States, 92093

San Francisco

University of California, San Francisco, San Francisco, California, United States, 94143

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Histologically confirmed PanNEN.
  • 2. New and existing PanNEN participants will be eligible (any grade, any stage, any age \> 18 years).
  • 3. Participants willing and able to comply with the study procedures.
  • 1. Inability to provide informed consent.
  • 2. For participants who have not had prior testing with a dedicated germline pane of at least 80 genes:
  • 1. Inability to speak/read a language supported by the germline testing station (GTS). The supported languages currently include English, Korean, Japanese, Vietnamese, Russian, Tagalog, Farsi, Spanish, Cantonese, Mandarin, and Arabic).
  • 2. Active hematologic malignancy.
  • 3. History of allogenic bone marrow transplant or stem cell transplant.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, San Francisco,

Emily Bergsland, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

2025-12-31